Myriad Genetics (MYGN) PT Lowered to $14 at Piper Sandler
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $3.13 +2.62%
Rating Summary:
7 Buy, 19 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 8 | New: 13
Rating Summary:
7 Buy, 19 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 8 | New: 13
Join SI Premium – FREE
Piper Sandler analyst William Quirk lowered the price target on Myriad Genetics (NASDAQ: MYGN) to $14.00 (from $20.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Calumet Specialty Products Partners (CLMT) PT Raised to $47 at UBS
- Septeni Holdings Co Ltd (4293:JP) PT Raised to JPY570 at Nomura/Instinet
- Dollar Tree (DLTR) PT Raised to $138 at Truist Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
